At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
In Brief
A Phase 1 clinical trial evaluating Everolimus, Laboratory Biomarker Analysis, and 2 other interventions for CNS Embryonal Tumor, Not Otherwise Specified and 6 related conditions. Completed, enrolled 22 participants across 12 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and everolimus may work better at treating malignant brain tumors.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Correlative studies
Given PO